JP2003529542A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003529542A5 JP2003529542A5 JP2001511882A JP2001511882A JP2003529542A5 JP 2003529542 A5 JP2003529542 A5 JP 2003529542A5 JP 2001511882 A JP2001511882 A JP 2001511882A JP 2001511882 A JP2001511882 A JP 2001511882A JP 2003529542 A5 JP2003529542 A5 JP 2003529542A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- etodolac
- alkyl
- viability
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 6
- NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 description 6
- 229960005293 etodolac Drugs 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- NNYBQONXHNTVIJ-QGZVFWFLSA-N (R)-etodolac Chemical compound C1CO[C@](CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-QGZVFWFLSA-N 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 3
- 229960001924 melphalan Drugs 0.000 description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/360,020 US6545034B1 (en) | 1999-07-23 | 1999-07-23 | Use of etodolac for the treatment of chronic lymphocytic leukemia |
| US09/360,020 | 1999-07-23 | ||
| US09/589,476 US7105560B1 (en) | 1999-07-23 | 2000-06-07 | Use of etodolac in the treatment of multiple myeloma |
| US09/589,476 | 2000-06-07 | ||
| PCT/US2000/040370 WO2001006990A2 (en) | 1999-07-23 | 2000-07-13 | Use of etodolac to treat cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003529542A JP2003529542A (ja) | 2003-10-07 |
| JP2003529542A5 true JP2003529542A5 (https=) | 2007-10-04 |
Family
ID=27000719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001511882A Pending JP2003529542A (ja) | 1999-07-23 | 2000-07-13 | 癌の治療のためのエトドラクの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7105560B1 (https=) |
| EP (1) | EP1204412A4 (https=) |
| JP (1) | JP2003529542A (https=) |
| AU (1) | AU785089B2 (https=) |
| CA (1) | CA2378371A1 (https=) |
| IL (1) | IL147748A0 (https=) |
| NO (1) | NO20020358L (https=) |
| WO (1) | WO2001006990A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5955504A (en) * | 1995-03-13 | 1999-09-21 | Loma Linda University Medical Center | Colorectal chemoprotective composition and method of preventing colorectal cancer |
| WO2000002555A1 (en) | 1998-07-09 | 2000-01-20 | Nardella Francis A | Methods and compositions for the treatment of chronic lymphocytic leukemia |
| US7151100B1 (en) * | 1999-07-23 | 2006-12-19 | The Regents Of The University Of California | Indole compounds useful for the treatment of cancer |
| US7361680B2 (en) * | 1999-07-23 | 2008-04-22 | The Regents Of The University Of California | Indole compounds useful for the treatment of cancer |
| US7129262B2 (en) | 1999-07-23 | 2006-10-31 | The Regents Of The University Of California | Indole compounds useful for the treatment of cancer |
| US7105560B1 (en) | 1999-07-23 | 2006-09-12 | The Regents Of The University Of California | Use of etodolac in the treatment of multiple myeloma |
| US6545034B1 (en) | 1999-07-23 | 2003-04-08 | The Regents Of The University Of California | Use of etodolac for the treatment of chronic lymphocytic leukemia |
| US20040152672A1 (en) * | 2000-08-09 | 2004-08-05 | Carson Dennis A. | Indole compounds useful for the treatment of cancer |
| AU2003295336A1 (en) | 2002-09-19 | 2004-04-08 | Dennis A. Carson | Use of etodoclac to treat hyperplasia |
| ITMI20031471A1 (it) | 2003-07-18 | 2005-01-19 | Chemi Spa | Processo per la racemizzazione dell'acido etodolico |
| US7467119B2 (en) * | 2003-07-21 | 2008-12-16 | Aureon Laboratories, Inc. | Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition |
| US7461048B2 (en) * | 2003-07-21 | 2008-12-02 | Aureon Laboratories, Inc. | Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition |
| US7483554B2 (en) | 2003-11-17 | 2009-01-27 | Aureon Laboratories, Inc. | Pathological tissue mapping |
| TW200524940A (en) * | 2003-10-02 | 2005-08-01 | Salmedix Inc | Indole derivatives |
| EP1728210A2 (en) * | 2004-02-27 | 2006-12-06 | Aureon Laboratories, Inc. | Methods and systems for predicting occurrence of an event |
| CA2575859A1 (en) | 2004-08-11 | 2006-02-23 | Aureon Laboratories, Inc. | Systems and methods for automated diagnosis and grading of tissue images |
| JP5156392B2 (ja) * | 2005-02-03 | 2013-03-06 | トポターゲット ユーケー リミテッド | Ｈｄａｃ阻害剤を用いる併用療法 |
| ITMI20060894A1 (it) | 2006-05-05 | 2007-11-06 | Univ Catania | Ciclodestrine funzionalizzate con etodolac come agenti di rilascio sito specifico |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL107185C (https=) | 1957-12-19 | |||
| US3843480A (en) | 1963-08-28 | 1974-10-22 | D Dreher | Dry dry transfer |
| US3948262A (en) | 1969-04-01 | 1976-04-06 | Alza Corporation | Novel drug delivery device |
| US3993073A (en) | 1969-04-01 | 1976-11-23 | Alza Corporation | Novel drug delivery device |
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US3939178A (en) | 1971-06-01 | 1976-02-17 | American Home Products Corporation | Certain pyrano [3,4-b]indoles and thiopyrano[3,4-b]indoles |
| US3843681A (en) | 1971-06-01 | 1974-10-22 | American Home Prod | 1-carboxamido pyrano(thiopyrano)(3,4-6)indole derivatives |
| US3974179A (en) | 1971-06-01 | 1976-08-10 | American Home Products Corporation | 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetamides and derivatives |
| US3948254A (en) | 1971-11-08 | 1976-04-06 | Alza Corporation | Novel drug delivery device |
| DE2226703A1 (de) | 1972-05-25 | 1973-12-13 | Schering Ag | Neue tetrahydrocarbazolderivate und verfahren zu ihrer herstellung |
| US4041169A (en) | 1975-03-05 | 1977-08-09 | Ayerst Mckenna And Harrison Ltd. | Pharmaceutical method for using pyrano-and thiopyranoindole derivatives |
| US4179503A (en) | 1978-05-08 | 1979-12-18 | American Home Products Corp. | 1-Hydroxyalkanamine pyrano[3,4-b]indole derivatives |
| US4337760A (en) | 1978-10-13 | 1982-07-06 | Adolf Schwimmer | Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals |
| US4310509A (en) | 1979-07-31 | 1982-01-12 | Minnesota Mining And Manufacturing Company | Pressure-sensitive adhesive having a broad spectrum antimicrobial therein |
| US4291015A (en) | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
| JPS5777617A (en) | 1980-10-20 | 1982-05-15 | Nichiban Co Ltd | Plaster for cardiac disease |
| IL61721A (en) | 1980-12-16 | 1984-03-30 | Blank Izhak | Nitroglycerin preparations |
| US4542013A (en) | 1981-07-08 | 1985-09-17 | Key Pharmaceuticals, Inc. | Trinitroglycerol sustained release vehicles and preparation therefrom |
| US4460562A (en) | 1982-01-06 | 1984-07-17 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing propranolol |
| US4485097A (en) | 1982-05-26 | 1984-11-27 | Massachusetts Institute Of Technology | Bone-equivalent and method for preparation thereof |
| US4542012A (en) | 1982-07-02 | 1985-09-17 | Minnesota Mining And Manufacturing Company | Film-forming composition containing an antimicrobial agent and methods |
| US4608249A (en) | 1982-11-02 | 1986-08-26 | Nitto Electric Industrial Co., Ltd. | Hydrophilic therapeutic material |
| IT1153909B (it) | 1982-12-17 | 1987-01-21 | Sogimi Srl | Polimeri reattivi per la cura di affezioni cutanee |
| GB8317576D0 (en) | 1983-06-29 | 1983-08-03 | Shaw A S W | Consumer tobacco products |
| US4597961A (en) | 1985-01-23 | 1986-07-01 | Etscorn Frank T | Transcutaneous application of nicotine |
| US4585877A (en) | 1985-05-06 | 1986-04-29 | American Home Products Corporation | Process for preparing 1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)-indole-1-acetic acid, etodolac |
| GB8514665D0 (en) | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
| US4748252A (en) | 1986-08-15 | 1988-05-31 | American Home Products Corporation | Substituted 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acids |
| US4686213A (en) | 1986-08-15 | 1987-08-11 | American Home Products Corporation | Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids |
| CA1299577C (en) | 1987-01-09 | 1992-04-28 | John W. Gillard | Tetrahydrocarbazole 1-alkanoic acids |
| JPS6452742A (en) | 1987-04-27 | 1989-02-28 | Syntex Pharma Int | Omega-quaternary ammonium alkyl ester and thioester of acidic non-steroidal antiinflammatory |
| DK0727994T3 (da) | 1992-03-13 | 2000-08-07 | Sepracor Inc | Anvendelse af antipyretiske og analgetiske præparater indeholdende optisk rent R-etodolac |
| JPH09511516A (ja) | 1994-04-12 | 1997-11-18 | カイロサイエンス・リミテッド | グルカミン誘導体を用いるエトドラックの分割法 |
| US5981592A (en) | 1995-03-13 | 1999-11-09 | Loma Linda University Medical Center | Method and composition for treating cystic fibrosis |
| US5955504A (en) | 1995-03-13 | 1999-09-21 | Loma Linda University Medical Center | Colorectal chemoprotective composition and method of preventing colorectal cancer |
| US6160018A (en) | 1995-03-13 | 2000-12-12 | Loma Linda University Medical Center | Prophylactic composition and method for alzheimer's Disease |
| US5599946A (en) | 1995-05-30 | 1997-02-04 | Teva Pharmaceutical Industries Ltd. | 3-(2-trialkylsilyloxy)ethyl-7-ethyl-1H-indoles and method for their preparation |
| CN1196679A (zh) * | 1995-07-19 | 1998-10-21 | 麦克公司 | 结肠腺瘤治疗方法 |
| US5968974A (en) | 1995-07-19 | 1999-10-19 | Merck & Co., Inc. | Method of treating colonic adenomas |
| US5780435A (en) | 1995-12-15 | 1998-07-14 | Praecis Pharmaceuticals Incorporated | Methods for treating prostate cancer with LHRH-R antagonists |
| WO1997048391A2 (en) | 1996-06-21 | 1997-12-24 | Advanced Research And Technology Institute | Methods and compositions comprising r-ibuprofen |
| US5776967A (en) | 1996-07-26 | 1998-07-07 | American Home Products Corporation | Pyranoindole inhibitors of COX--2 |
| US6054432A (en) | 1996-09-12 | 2000-04-25 | Asta Medica Aktiengesellschaft | Means for treating prostate hypertrophy and prostate cancer |
| IE960761A1 (en) | 1996-10-31 | 1998-05-06 | Univ Dublin City | Combinations for use in increasing the potency of a¹substrate for multidrug resistance related protein |
| ATE493983T1 (de) * | 1996-11-05 | 2011-01-15 | Childrens Medical Center | Thalidomide und dexamethason für die behandlung von tumors |
| US6552055B2 (en) * | 1996-12-11 | 2003-04-22 | Dana-Farber Cancer Institute | Methods and pharmaceutical compositions for inhibiting tumor cell growth |
| US6110955A (en) | 1997-03-11 | 2000-08-29 | Beacon Laboratories, Inc. | Metabolically stabilized oxyalkylene esters and uses thereof |
| US5939455A (en) | 1997-03-11 | 1999-08-17 | Beacon Laboratories, Inc. | Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives |
| WO2000002555A1 (en) * | 1998-07-09 | 2000-01-20 | Nardella Francis A | Methods and compositions for the treatment of chronic lymphocytic leukemia |
| US7197228B1 (en) | 1998-08-28 | 2007-03-27 | Monroe David A | Multifunction remote control system for audio and video recording, capture, transmission and playback of full motion and still images |
| US7105560B1 (en) | 1999-07-23 | 2006-09-12 | The Regents Of The University Of California | Use of etodolac in the treatment of multiple myeloma |
| AUPQ849900A0 (en) | 2000-06-30 | 2000-07-27 | Dbl Australia Pty Ltd. | Injectable composition |
| US20020042375A1 (en) | 2000-07-05 | 2002-04-11 | Heimbrook David C. | Method of treating cancer |
| AU8322401A (en) | 2000-08-09 | 2002-02-18 | Univ California | Indole compounds useful for the treatment of cancer |
| WO2002085327A2 (en) | 2001-04-18 | 2002-10-31 | Oraltech Pharmaceuticals, Inc. | Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract |
| US20030004142A1 (en) | 2001-04-18 | 2003-01-02 | Prior Christopher P. | Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway |
-
2000
- 2000-06-07 US US09/589,476 patent/US7105560B1/en not_active Expired - Fee Related
- 2000-07-13 JP JP2001511882A patent/JP2003529542A/ja active Pending
- 2000-07-13 IL IL14774800A patent/IL147748A0/xx unknown
- 2000-07-13 EP EP00961986A patent/EP1204412A4/en not_active Withdrawn
- 2000-07-13 CA CA002378371A patent/CA2378371A1/en not_active Abandoned
- 2000-07-13 AU AU73859/00A patent/AU785089B2/en not_active Ceased
- 2000-07-13 WO PCT/US2000/040370 patent/WO2001006990A2/en not_active Ceased
-
2002
- 2002-01-23 NO NO20020358A patent/NO20020358L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003529542A5 (https=) | ||
| Ishikawa et al. | Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts | |
| Angulo et al. | Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid | |
| Seitz et al. | Alcohol and cancer | |
| Oudard et al. | Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme | |
| EP1471902B1 (en) | Compositions for use in methods for treating hearing loss | |
| US8029770B2 (en) | Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer | |
| Hennequin et al. | Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells | |
| MA28740B1 (fr) | Methodes de traitement d'infections endobronchiques | |
| US8138158B2 (en) | Compositions and methods for therapy for diseases characterized by defective chloride transport | |
| HUP0203870A2 (hu) | Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény | |
| JP2008520746A (ja) | アデノシンａ３受容体アンタゴニストを用いる癌及びｈｉｆ−１が介在する疾患の促進的治療 | |
| US7105560B1 (en) | Use of etodolac in the treatment of multiple myeloma | |
| KR100400509B1 (ko) | 메토트렉세이트유도체를함유하는약제 | |
| Ishida et al. | Inhibition of antigen-induced airway hyperresponsiveness, but not acute hypoxia nor airway eosinophilia, by an antagonist of platelet-activating factor. | |
| Fetoni et al. | The protective role of tiopronin in cisplatin ototoxicity in Wistar rats | |
| Davis et al. | Eosinophilic alveolitis in acute respiratory failure: A clinical marker for a non-infectious etiology | |
| JPH10507449A (ja) | 血管再狭窄阻害用医薬の製造のためのザプリナストの使用 | |
| Nagler | Extended-term effects of head and neck irradiation in a rodent | |
| Fujimori et al. | Inhibition by nifedipine of adherence-and activated macrophage-induced death of human gingival fibroblasts | |
| Okui et al. | Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction | |
| US20040082558A1 (en) | Administration of estradiol metabolites for inhibition of drug-induced nephrotoxicity | |
| WO2002094199A3 (en) | METHOD OF INCREASING ANTI-NeuGc ANTIBODY LEVELS IN BLOOD | |
| Lelieveld et al. | Effectiveness of P-aminobenzyol-O-phenylenediamine (Goe 1734) against mouse, rat, and human tumour cells | |
| Kessinger et al. | Use of DTIC in the Malignant Carcinoid Syndrome 1, 2, 3 |